Author:
Zhang Pengyu,Song Xiang,Sun Luhao,Li Chao,Liu Xiaoyu,Bao Jiaying,Tian Zhaokun,Wang Xinzhao,Yu Zhiyong
Abstract
AbstractThis study is aimed to develop and validate a novel nomogram model that can preoperatively predict axillary lymph node pathological complete response (pCR) after NAT and avoid unnecessary axillary lymph node dissection (ALND) for breast cancer patients. A total of 410 patients who underwent NAT and were pathologically confirmed to be axillary lymph node positive after breast cancer surgery were included. They were divided into two groups: patients with axillary lymph node pCR and patients with residual node lesions after NAT. Then the nomogram prediction model was constructed by univariate and multivariate logistic regression. The result of multivariate logistic regression analysis showed that molecular subtypes, molybdenum target (MG) breast, computerized tomography (CT) breast, ultrasound (US) axilla, magnetic resonance imaging (MRI) axilla, and CT axilla (all p < 0.001) had a significant impact on the evaluation of axillary lymph node status after NAT. The nomogram score appeared that AUC was 0.832 (95% CI 0.786–0.878) in the training cohort and 0.947 (95% CI 0.906–0.988) in the validation cohort, respectively. The decision curve represented that the nomogram has a positive predictive ability, indicating its potential as a practical clinical tool.
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
2. Sun, C. et al. Clinical effects of neoadjuvant chemotherapy in treating breast cancer. Cancer Biother. Radiopharm. 36(2), 174–179 (2021).
3. Moo, T. A. et al. Overview of breast cancer therapy. PET Clin. 13(3), 339–354 (2018).
4. Kaufmann, M. et al. Locoregional treatment of primary breast cancer: Consensus recommendations from an International Expert Panel. Cancer 116(5), 1184–1191 (2010).
5. Baselga, J. et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial. Lancet 379(9816), 633–640 (2012).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献